The Lalji Family ALS Award

The Lalji Family ALS Award is a global prize celebrating excellence in…

Words Maaike Dubbeldam.Published August 26, 2021
The Lalji Family ALS Award

The Lalji Family ALS Award is a global prize celebrating excellence in research for an individual or team of investigators who are making transformative breakthroughs in the science of repair of neurological function in ALS. The goal is to identify and recognize therapies and modalities to regain lost function in ALS patients.

 

Prize Criteria

The Lalji Family ALS Award is accepting nominations for individual or team of investigators who have made significant progress in the ALS field impacting the repair of neuronal degeneration in ALS. Examples include but are not limited to:
  • Identification of key modulators of axonal health and degeneration
  • Discoveries to explore changes in axonal transport
  • Novel methods to increase and improve endogenous neurogenesis
  • Cell therapies to target and improve neuronal and/or glial regeneration
  • Restoring nerve muscle communication
  • Immune system inhibition to decrease inflammation and improve neuronal regeneration
  • Discovery of intra-cellular mechanisms to enhance repair and regeneration

 

Timeline for Submission
  • Release Date: July 19, 2021
  • Nomination Due Date: September 10, 2021
  • Notification to successful candidate: Fall 2021
  • Presentation of award: Virtual 32nd International Symposium on ALS/MND December 2021

 

Download Nomination Form here.  Submit completed nomination form and supporting documents as a single PDF to healeycenterforals@mgh.harvard.edu

 

Award: $40,000 USD 

 

To learn more about the Sean M. Healey and AMG Center for ALS click here


Share

Related news

More patients eligible for treatment research through innovative study design
More patients eligible for treatment research through innovative study design
Due to a new trial design for treatment research, more ALS patients […]
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Amylyx Pharmaceuticals and TRICALS to collaborate on phase 3 clinical trial
Today, Amylyx Pharmaceuticals provided an update on its plans to advance its […]
Retrotope announces initiation of RT001 study in people with ALS
Retrotope announces initiation of RT001 study in people with ALS
Retrotope Inc has announced that the first participants have been enrolled in […]
Virtual ENCALS meeting 2021
Virtual ENCALS meeting 2021
This year, ENCALS (European Network to Cure ALS) will be organising their […]